Table 1.

Characteristics of the analyzed population.

Parametera (%, except as noted)	Pneumococcal Conjugate Vaccine 7					Pneumococcal Polysaccharide Vaccine					P- Valueb
	All Subjects	Immune Stratum				All Subjects	Immune Stratum
		1	2	3	4		1	2	3	4
N	36	0	14	14	8	31	1	10	12	8
Age
Median, years	13.8	NAc	15.5	14.2	10.8	14.6	21.9	15.1	13.4	12.8	0.55
Range, years	8.3–21.8					8.5–21.9
Interquartile range, years	12.0–15.8					11.1–16.6
Male sex	42	NA	36	50	38	55	0	60	50	63	0.33
Race/ethnicity											0.78
White Non-Hispanic	17	NA	21	14	13	10	0	0	25	0
Black Non-Hispanic	61	NA	50	79	50	65	100	80	42	75
Hispanic	22	NA	29	7	38	26	0	20	33	25
Other	0	NA	0	0	0	0	0	0	0	0
CDC clinical classification											0.39
N (not symptomatic)	6	NA	0	7	12	13	0	0	33	0
A (mildly symptomatic)	22	NA	21	14	38	35	0	40	33	38
B (moderately symptomatic)	47	NA	36	57	50	32	0	30	17	62
C (severely symptomatic)	25	NA	43	21	0	19	100	30	17	0
Pre-HAART Nadir CD4%
Median	16	NA	11	18	30	18	4	9	18	32	0.67
<15%	39	NA	100	0	0	35	100	100	0	0	0.95
15%–<25%	39	NA	0	100	0	39	0	0	100	0
≥25%	22	NA	0	0	100	26	0	0	0	100
P1024 Screening CD4%
Median	33	NA	31	33	40	35	12	28	38	37	0.88
<15%	0	NA	0	0	0	3	100	0	0	0	0.33
15–<25%	14	NA	29	7	0	6	0	20	0	0
≥25%	86	NA	71	93	100	90	0	80	100	100
P1024 HIV RNA level
≤400 copies/mL	78	NA	57	93	88	68	0	50	75	88	0.63
401–5000 copies/mL	11	NA	21	0	13	13	0	10	17	13
>5000 copies/mL	11	NA	21	7	0	19	100	40	8	0
P1061s CD4%
Median	33	NA	33	29	35	34	0	29	36	38	0.31
<15%	8	NA	0	21	0	10	100	20	0	0	1.00
15–25%	11	NA	14	14	0	13	0	20	17	0
≥25%	81	NA	86	64	100	77	0	60	83	100
P1061s HIV RNA level
≤400 copies/mL	58	NA	57	57	63	74	0	60	92	75	0.34
401–5000 copies/mL	22	NA	21	14	38	10	0	20	8	0
>5000 copies/mL	19	NA	21	29	0	16	100	20	0	25
Interval, P1024 week 16 (PPV dose) to P1061s entry
Median, years	4.3	NA	4.2	4.3	4.2	4.2	4.1	4.3	4.2	4.1	0.20
Range, years	4.0–4.8					3.8–4.5
Percent not receiving
HAART at P1061s entry	11	NA	7	14	12	6	100	0	0	12	0.68

Note: N = number of subjects in each subgroup.

^aData are percentage of subjects, unless otherwise indicated.

^bComparison of subjects who received pneumococcal conjugate vaccine (immune strata combined) v. subjects who received pneumococcal polysaccharide vaccine (immune strata combined).

^cNot applicable.